Zimmer Biomet Holdings, Inc. (ZBH)
ZBH Stock Might Rise Following FDA Nod for OsseoFit
Zimmer Biomet's OsseoFit Stemless Shoulder System gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Reasons to Retain ZBH Stock in Your Portfolio for Now
Zimmer Biomet's robust efforts to expand market share and a gradually stabilizing musculoskeletal market appear promising.
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
Zimmer Biomet's Persona SoluTion Porous Plasma Spray Femur gets FDA 510(k) approval. The company expects to launch the system in the first quarter of 2025.
Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee
Zimmer Biomet receives FDA nod for the Oxford Cementless Partial Knee. It is a PMA Supplement approval.
ZBH Stock Gains From Receiving CE Mark for Persona Revision Knee System
Zimmer Biomet gets CE Mark Certification for Persona Revision Knee System, followed by the successful introduction in the United States and other markets.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts
On Wednesday, Zimmer Biomet Holdings, Inc ZBH reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates.
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed
Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024.
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2024 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants David DeMartino – Senior Vice President-Investor Relations Ivan Tornos – President and Chief Executive Officer Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain Conference Call Participants Travis Steed – Bank of America Vik Chopra – Wells Fargo David Roman – Goldman Sachs Allen Gong – JPMorgan Matthew O'Brien – Piper Sandler Chris Pasquale – Nephron Steve Lichtman – Oppenheimer Sophia Knopp – Evercore ISI Richard Newitter – Truist Securities Jeff Johnson – Baird Caitlin Cronin – Canaccord Mike Matson – Needham & Company Shagun Singh – RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024.
Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Implant maker Zimmer Biomet lowers full-year profit forecast
Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations.
